The FDA has warned that ketamine and compounded ketamine products aren’t approved to deal with any psychiatric disorder. This usually means that they haven’t been established to generally be Protected or productive. In 2019, the FDA approved a nasal spray called esketamine (Spravato) that’s derived from ketamine for treatment-resistant depres